诺和诺德股价创5年新低

Core Viewpoint - Hims has launched a low-priced oral version of the weight loss drug semaglutide at $49, impacting the stock prices of major competitors Novo Nordisk and Eli Lilly, with Novo Nordisk's stock dropping 8% and Eli Lilly's 7% on February 5, 2026 [3][4]. Group 1: Market Impact - Hims' introduction of a generic version of semaglutide is seen as a significant threat to Novo Nordisk, which has experienced a nearly 27% decline in stock price over the past five trading days, reducing its market capitalization to under $150 billion [3]. - The launch of Hims' generic drug is expected to pressure the market for semaglutide, as it is priced $100 lower than Novo Nordisk's offering [4]. Group 2: Legal and Regulatory Context - Hims' sale of the generic drug operates in a legal "gray area," as it is not classified as an FDA-approved generic, raising concerns about the quality and safety of the drug [4][5]. - The FDA has previously warned Hims about misleading claims regarding the similarity of its product to FDA-approved drugs, indicating potential regulatory actions against such companies [5]. Group 3: Competitive Landscape - Analysts suggest that Eli Lilly's upcoming oral weight loss drug may become the next target for generic manufacturers, highlighting ongoing market dynamics and regulatory scrutiny [7]. - Novo Nordisk has announced plans to take legal action against Hims, asserting that the latter's practices pose significant risks to patient safety and violate intellectual property rights [4].